The Claim
In patients at high cardiovascular risk, the addition of ezetimibe to statin therapy has no meaningful difference in the incidence of muscle-related adverse events compared to statin therapy alone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people at high risk of heart disease, adding ezetimibe to statin medication does not result in more muscle-related side effects than taking statins alone.
See the scientific wording
Adding ezetimibe to statin therapy in patients at high cardiovascular risk does not increase the risk of myopathy, with moderate-certainty evidence indicating no meaningful difference in muscle-related adverse events compared to statin therapy alone.
Ezetimibe blocks cholesterol absorption in the gut but does not affect how statins work in muscle cells. Statins can sometimes cause muscle stress by reducing cholesterol and coenzyme Q10, but adding ezetimibe doesn’t make this worse because it doesn’t interfere with those processes in muscle tissue.
What the research says
1 studyFor people at high risk of heart disease, adding ezetimibe to their statin pill doesn’t make muscle pain or damage worse than statins alone—studies show no extra risk.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.